Loading
A phase 2 trial of ABSK061, CAPOX in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase 2 Clinical Study of ABSK061 and ABSK043 is a phase 2 interventional study registered as NCT06632262 by Abbisko Therapeutics Co, Ltd, with 202 participants planned, started 2024-11-13 and due to reach its primary completion in 2029-11-30. Interventions recorded: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX. Conditions listed: HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/